Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

Q2 Medicine

Journal of Buon Pub Date : 2021-09-01

Bulent Erdogan, Osman Kostek, Muhammet Bekir Hacioglu, Ali Gokyer, Ahmet Kucukarda, Erkan Ozcan, Ivo Gokmen, Sernaz Uzunoglu, Irfan Cicin

{"title":"Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?","authors":"Bulent Erdogan, Osman Kostek, Muhammet Bekir Hacioglu, Ali Gokyer, Ahmet Kucukarda, Erkan Ozcan, Ivo Gokmen, Sernaz Uzunoglu, Irfan Cicin","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: To demonstrate whether early changes in systemic inflammatory markers are related with pazopanib treatment response in soft tissue sarcoma and renal cell carcinoma.Methods: Forty-one patients with metastatic clear cell renal carcinoma (mRCC) (n=22) and advanced stage soft tissue sarcoma (STS) (n=19) were assessed. Systemic inflammatory markers such as neutrophils, lymphocytes, c-reactive protein (CRP), mean platelet volume (MPV), lactate dehydrogenase (LDH) and neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at both baseline and 1-month of pazopanib treatment were obtained and their relation with the first radiological response about 3-months later after pazopanib treatment was evaluated.Results: Disease control rate (DCR) at the first initial radiological evaluation was 58.5 % for all, it was 77.3% for the RCC group and 36.8% in the STS group. Serum neutrophil, NLR and CRP levels were significantly decreased from baseline in RCC patients who had DCR with pazopanib treatment. Also, serum CRP levels after pazopanib treatment was significantly lower in RCC patients who had DCR (+) rather than those who progressed.Conclusions: Early decline in serum CRP, neutrophil and NLR levels in RCC patients who received pazopanib at the first month was significantly associated with disease control, assuming a predictive role for the first radiological assessment. However, there was no significant association between change in serum inflammatory marker levels and disease control in STS patients.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":" ","pages":"2196-2201"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To demonstrate whether early changes in systemic inflammatory markers are related with pazopanib treatment response in soft tissue sarcoma and renal cell carcinoma.

Methods: Forty-one patients with metastatic clear cell renal carcinoma (mRCC) (n=22) and advanced stage soft tissue sarcoma (STS) (n=19) were assessed. Systemic inflammatory markers such as neutrophils, lymphocytes, c-reactive protein (CRP), mean platelet volume (MPV), lactate dehydrogenase (LDH) and neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at both baseline and 1-month of pazopanib treatment were obtained and their relation with the first radiological response about 3-months later after pazopanib treatment was evaluated.

Results: Disease control rate (DCR) at the first initial radiological evaluation was 58.5 % for all, it was 77.3% for the RCC group and 36.8% in the STS group. Serum neutrophil, NLR and CRP levels were significantly decreased from baseline in RCC patients who had DCR with pazopanib treatment. Also, serum CRP levels after pazopanib treatment was significantly lower in RCC patients who had DCR (+) rather than those who progressed.

Conclusions: Early decline in serum CRP, neutrophil and NLR levels in RCC patients who received pazopanib at the first month was significantly associated with disease control, assuming a predictive role for the first radiological assessment. However, there was no significant association between change in serum inflammatory marker levels and disease control in STS patients.

本刊更多论文

在接受帕唑帕尼治疗的患者中，全身性炎症标志物的早期改变是否与治疗反应相关?

目的:探讨软组织肉瘤和肾细胞癌患者全身炎症标志物的早期变化是否与帕唑帕尼治疗反应有关。方法:对41例转移性透明细胞肾癌(mRCC) (n=22)和晚期软组织肉瘤(STS) (n=19)进行分析。获得帕唑帕尼治疗基线和治疗1个月时的全身炎症标志物，如中性粒细胞、淋巴细胞、c反应蛋白(CRP)、平均血小板体积(MPV)、乳酸脱氢酶(LDH)、中性粒细胞-淋巴细胞比值(NLR)和血小板-淋巴细胞比值(PLR)，并评估它们与帕唑帕尼治疗3个月后首次放射反应的关系。结果:首次影像学检查时疾病控制率(DCR)为58.5%，RCC组为77.3%，STS组为36.8%。在接受帕唑帕尼治疗的RCC患者中，血清中性粒细胞、NLR和CRP水平较基线显著降低。此外，帕唑帕尼治疗后，DCR(+)的RCC患者的血清CRP水平明显低于进展期患者。结论:接受帕唑帕尼治疗的RCC患者在第一个月早期血清CRP、中性粒细胞和NLR水平的下降与疾病控制显著相关，假设首次放射评估具有预测作用。然而，STS患者血清炎症标志物水平的变化与疾病控制之间没有显著相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.